MedTrace Logo

Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)

NCT00979901 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1577

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

This study will evaluate the ability of montelukast to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine and placebo.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

Comparator: montelukast

10 mg montelukast tablet given once daily at bedtime for 2 weeks

DRUG

Comparator: loratadine

10 mg loratadine tablet given once daily at bedtime for 2 weeks

DRUG

Comparator: placebo

placebo tablet given once daily at bedtime for 2 weeks

DRUG

Comparator: montelukast/loratadine

montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31
Primary Completion
2000-05-31
Completion
2000-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979901 on ClinicalTrials.gov